Mark Marion Kowalski
79 works · 3,486 citations · h-index 23
Top works
- Functional Regions of the Envelope Glycoprotein of Human Immunodeficiency Virus Type 1
- A soluble CD4 protein selectively inhibits HIV replication and syncytium formation
- Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants
- Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine.
- Cis-acting sequences responsive to the rev gene product of the human immunodeficiency virus.
- Attenuation of human immunodeficiency virus type 1 cytopathic effect by a mutation affecting the transmembrane envelope glycoprotein
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial
- Partial purification of Rho (D) antigen from Rh positive and negative erythrocytes.
- ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
- Antibodies to CD4 in individuals infected with human immunodeficiency virus type 1.
- Effects on CD4 binding of anti-peptide sera to the fourth and fifth conserved domains of HIV-1 gp120.
- A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-Guérin
- High level of surface CD4 prevents stable human immunodeficiency virus infection of T-cell transfectants
- Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis
- A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients
- The Role of Membrane Phospholipid in Expression of Erythrocyte Rh0(D) Antigen Activity
- Single-dose pharmacokinetic study of rapidly dispersing diclofenac potassium formulations in healthy volunteers
- Momelotinib reduces transfusion requirements in patients with myelofibrosis
- An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,